Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Perspective

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Jan 12, 2021 12:50pm

125 Views

Post# 32276740

RE:Perspective

Had they made exactly the same deal with a big pharma I would have opened my best bottle!!!!

jeffm34 wrote:

To put this deal in perspective, the company just sold 30% of all future revenues for Egrifta, Tragarzo, any Nash drug, and any oncology drug for $40M.

that would be the equivalent of them signing a deal with a big Pharma company and saying give us 40M and you can have a third of our company and you don't have to do anything else. You don't have to fund 30% of our trial costs, you don't have to fund 30% of our marketing. Just take 30% of our revenues and we will pay 100% of the expenses.

I can't imagine experienced business people being this incompetent. That leaves only two explanations.

1. The prospects for the company is pretty dire.

2. They were promised a second round of financing by these investment banks at a share price much higher than this round.